EGMN -- A Food and Drug Administration advisory panel on Sept. 20 unanimously voted to recommend that dabigatran, an orally administered direct thrombin inhibitor, be approved for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
